Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. 2018

Ayman Oweida, and Andy Phan, and Benjamin Vancourt, and Tyler Robin, and Mohammad K Hararah, and Shilpa Bhatia, and Dallin Milner, and Shelby Lennon, and Laura Pike, and David Raben, and Bryan Haugen, and Nikita Pozdeyev, and Rebecca Schweppe, and Sana D Karam
1 Department of Radiation Oncology, University of Colorado Denver-Anschutz Medical Campus , Aurora, Colorado.

Anaplastic thyroid cancer (ATC) is an aggressive and highly lethal disease with poor outcomes and resistance to therapy. Despite multimodality treatment, including radiation therapy and chemotherapy, response rates remain <15%, with a median time to progression of less than three months. Recent advances in radiotherapy (RT) delivery and gene-expression profiling may help guide patient selection for personalized therapy. The purpose of this study was to characterize the response to radiation in a panel of ATC cell lines and to test alternative RT fractionation schedules for overcoming radioresistance. The cellular response to radiation was characterized based on clonogenic assays. Radiation response was correlated with microarray gene-expression data. Hypofractionated and conventional RT was tested in an orthotopic ATC tumor model, and tumor growth was assayed locally and distantly with in vivo and ex vivo bioluminescence imaging. A spectrum of radiosensitivities was observed in ATC cell lines. Radioresistant cell lines had higher levels of CXCR4 compared to radiosensitive cell lines. Compared to conventionally fractionated RT, hypofractionated RT resulted in significantly improved tumor growth delay, decreased regional and distant metastases, and improved overall survival. The findings demonstrate the heterogeneity of response to radiation in ATC tumors and the superiority of hypofractionated RT in improving local control, metastatic spread, and survival in preclinical models. These data support the design of clinical trials targeting radioresistant pathways in combination with hypofractionated RT.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069473 Radiation Dose Hypofractionation A treatment schedule in which the total dose of radiation is divided into large doses but fewer exposure times. Hypofractionated Dose, Radiation,Radiotherapy Dose Hypofractionation,Radiotherapy Minibeams,Dose Hypofractionation, Radiation,Dose Hypofractionation, Radiotherapy,Hypofractionation, Radiation Dose,Hypofractionation, Radiotherapy Dose,Hypofractionations, Radiotherapy Dose,Minibeam, Radiotherapy,Radiation Hypofractionated Dose,Radiotherapy Minibeam
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013964 Thyroid Neoplasms Tumors or cancer of the THYROID GLAND. Cancer of Thyroid,Thyroid Cancer,Cancer of the Thyroid,Neoplasms, Thyroid,Thyroid Adenoma,Thyroid Carcinoma,Adenoma, Thyroid,Adenomas, Thyroid,Cancer, Thyroid,Cancers, Thyroid,Carcinoma, Thyroid,Carcinomas, Thyroid,Neoplasm, Thyroid,Thyroid Adenomas,Thyroid Cancers,Thyroid Carcinomas,Thyroid Neoplasm
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Ayman Oweida, and Andy Phan, and Benjamin Vancourt, and Tyler Robin, and Mohammad K Hararah, and Shilpa Bhatia, and Dallin Milner, and Shelby Lennon, and Laura Pike, and David Raben, and Bryan Haugen, and Nikita Pozdeyev, and Rebecca Schweppe, and Sana D Karam
January 2024, European thyroid journal,
Ayman Oweida, and Andy Phan, and Benjamin Vancourt, and Tyler Robin, and Mohammad K Hararah, and Shilpa Bhatia, and Dallin Milner, and Shelby Lennon, and Laura Pike, and David Raben, and Bryan Haugen, and Nikita Pozdeyev, and Rebecca Schweppe, and Sana D Karam
July 2018, Thyroid : official journal of the American Thyroid Association,
Ayman Oweida, and Andy Phan, and Benjamin Vancourt, and Tyler Robin, and Mohammad K Hararah, and Shilpa Bhatia, and Dallin Milner, and Shelby Lennon, and Laura Pike, and David Raben, and Bryan Haugen, and Nikita Pozdeyev, and Rebecca Schweppe, and Sana D Karam
April 2013, Journal of visualized experiments : JoVE,
Ayman Oweida, and Andy Phan, and Benjamin Vancourt, and Tyler Robin, and Mohammad K Hararah, and Shilpa Bhatia, and Dallin Milner, and Shelby Lennon, and Laura Pike, and David Raben, and Bryan Haugen, and Nikita Pozdeyev, and Rebecca Schweppe, and Sana D Karam
September 2020, Cancers,
Ayman Oweida, and Andy Phan, and Benjamin Vancourt, and Tyler Robin, and Mohammad K Hararah, and Shilpa Bhatia, and Dallin Milner, and Shelby Lennon, and Laura Pike, and David Raben, and Bryan Haugen, and Nikita Pozdeyev, and Rebecca Schweppe, and Sana D Karam
March 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
Ayman Oweida, and Andy Phan, and Benjamin Vancourt, and Tyler Robin, and Mohammad K Hararah, and Shilpa Bhatia, and Dallin Milner, and Shelby Lennon, and Laura Pike, and David Raben, and Bryan Haugen, and Nikita Pozdeyev, and Rebecca Schweppe, and Sana D Karam
February 2024, Discover. Oncology,
Ayman Oweida, and Andy Phan, and Benjamin Vancourt, and Tyler Robin, and Mohammad K Hararah, and Shilpa Bhatia, and Dallin Milner, and Shelby Lennon, and Laura Pike, and David Raben, and Bryan Haugen, and Nikita Pozdeyev, and Rebecca Schweppe, and Sana D Karam
January 2011, Urologic oncology,
Ayman Oweida, and Andy Phan, and Benjamin Vancourt, and Tyler Robin, and Mohammad K Hararah, and Shilpa Bhatia, and Dallin Milner, and Shelby Lennon, and Laura Pike, and David Raben, and Bryan Haugen, and Nikita Pozdeyev, and Rebecca Schweppe, and Sana D Karam
January 2023, Frontiers in immunology,
Ayman Oweida, and Andy Phan, and Benjamin Vancourt, and Tyler Robin, and Mohammad K Hararah, and Shilpa Bhatia, and Dallin Milner, and Shelby Lennon, and Laura Pike, and David Raben, and Bryan Haugen, and Nikita Pozdeyev, and Rebecca Schweppe, and Sana D Karam
January 2001, Annali italiani di chirurgia,
Ayman Oweida, and Andy Phan, and Benjamin Vancourt, and Tyler Robin, and Mohammad K Hararah, and Shilpa Bhatia, and Dallin Milner, and Shelby Lennon, and Laura Pike, and David Raben, and Bryan Haugen, and Nikita Pozdeyev, and Rebecca Schweppe, and Sana D Karam
March 2024, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Copied contents to your clipboard!